You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDANT CANDLES WITH PNEUMATIC CIRCULATORS

    SBC: AirLIft Environmental LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Clean water is one of the most basic societal needs in the world Few situations incite more public outcry than when a community learns that their drinking water has been tainted Two of the biggest threats to groundwater quality in the U S are contamination from either chlorinated solvents or petroleum Left unattended the size and scope of the problems asso ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. OTOREFLECTANCE ASSESSMENT OF MIDDLE-EAR FUNCTIONING

    SBC: Sonicom, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Otoreflectance (OR) is a new class of hearing-test instruments utilizing acoustic signals presented and recorded in the ear canal. OR instruments address the following limitations in existing instruments to screen and diagnose middle-ear function: (1) detection of otitis media, (2) prediction of conductive hearing loss, (3) detection of middle-ear dysfunction i ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. RADIOGRAPHIC CONTRAST TO DIFFERENTIATE CAVITATED FROM NON-CAVITATED DENTAL CARIES

    SBC: FIREFLY HEALTH INNOVATIONS NE, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant This project aims to improve the accuracy of tests for early tooth decay dental caries specifically for interproximal surfaces where the posterior teeth abut one another In these regions there is no physical space to visually inspect or probe for caries Instead dentists rely on bitewing X rays BWs But dentists cannot tell whether lucencies observed ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins

    SBC: LI-COR, Inc.            Topic: 100

    DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Response-Selective C5a Agonist for the Treatment of Asthma

    SBC: Prommune, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): An unmet need in the treatment of allergic asthma is an effective therapeutic strategy that focuses on an underlying cause of the disease rather than merely treating or managing its symptoms. At least one well- accepted underlying contributor to the pathophysiologic expression of asthma is an over-expressed and dysregulated T helper type 2 (Th2)-mediated immun ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma

    SBC: ADDUCTNE LLC            Topic: 102

    In 2020 alone, pancreatic cancer is estimated to have resulted in 47,050 deaths in the U.S. making it the fourth leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) makes up greater than 90% of all pancreatic cancer diagnoses and has an overall five-year survival rate of just 10%. New therapeutic options are needed to improve the poor prognosis for patients with PDAC. Ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer

    SBC: ACTORIUS PHARMACEUTICALS, LLC            Topic: 100

    DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government